Mutations in isocitrate dehydrogenase (IDH) genes are commonly observed in patients with AML, with IDH2 mutations detected at around 10–15% of all patients at AML diagnosis [5, 6]. The gene discussed is IDH2; the disease is acute myeloid leukemia.